Eli Lilly and Company (NYSE:LLY) Stock Unloaded by Rep. Michael A. Rulli

Representative Michael A. Rulli (Republican-Ohio) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on November 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on November 4th. The trade occurred in the Representative’s “MERRILL LYNCH SIMPLE MANAGED ACCOUNT” account.

Representative Michael A. Rulli also recently made the following trade(s):

  • Sold $1,001 – $15,000 in shares of Costco Wholesale (NASDAQ:COST) on 11/12/2026.
  • Sold $1,001 – $15,000 in shares of Lumentum (NASDAQ:LITE) on 11/4/2026.
  • Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/4/2026.
  • Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 11/4/2026.
  • Sold $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 10/28/2026.
  • Sold $50,001 – $100,000 in shares of Alphabet (NASDAQ:GOOG) on 10/16/2026.
  • Sold $1,001 – $15,000 in shares of WesBanco (NASDAQ:WSBC) on 10/16/2026.
  • Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 9/28/2026.
  • Sold $1,001 – $15,000 in shares of Wells Fargo & Company (NYSE:WFC) on 9/3/2026.
  • Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 9/3/2026.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,352.18 on Friday. Eli Lilly and Company has a 12 month low of $850.51 and a 12 month high of $1,475.25. The stock has a market cap of $1.27 trillion, a PE ratio of 43.89, a price-to-earnings-growth ratio of 1.65 and a beta of 0.40. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The company’s fifty day moving average price is $1,263.45 and its 200-day moving average price is $1,117.53.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. During the same period in the prior year, the firm posted $7.02 earnings per share. The company’s quarterly revenue was up 38.6% on a year-over-year basis. On average, equities analysts expect that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares in the company, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Prostatis Group LLC grew its holdings in Eli Lilly and Company by 33.4% in the third quarter. Prostatis Group LLC now owns 719 shares of the company’s stock valued at $832,000 after purchasing an additional 180 shares during the last quarter. Innovative Asset Advisors Group LLC grew its position in shares of Eli Lilly and Company by 2.5% in the third quarter. Innovative Asset Advisors Group LLC now owns 767 shares of the company’s stock valued at $888,000 after purchasing an additional 19 shares during the last quarter. Connors Investor Services Inc. grew its position in shares of Eli Lilly and Company by 1.0% in the third quarter. Connors Investor Services Inc. now owns 18,497 shares of the company’s stock valued at $21,403,000 after purchasing an additional 183 shares during the last quarter. Defiance ETFs LLC raised its position in shares of Eli Lilly and Company by 28.1% during the 3rd quarter. Defiance ETFs LLC now owns 4,553 shares of the company’s stock worth $5,268,000 after purchasing an additional 999 shares during the last quarter. Finally, Kestra Advisory Services LLC lifted its stake in Eli Lilly and Company by 10.6% in the 3rd quarter. Kestra Advisory Services LLC now owns 130,765 shares of the company’s stock valued at $151,306,000 after buying an additional 12,584 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Top Eli Lilly and Company Stories

Investors following LLY have been watching these stories:

  • Positive Sentiment: Health Canada approved Mounjaro (tirzepatide) to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, broadening its potential use. Article: Health Canada approves Lilly’s Mounjaro
  • Positive Sentiment: Analyst and investor endorsements—including Jefferies’ reported highest Street price target and Eli Lilly’s inclusion among Ken Fisher’s fastest-growing top positions—provide supportive sentiment, though they do not guarantee further gains. Article: Jefferies has Wall Street’s highest target on Eli Lilly
  • Negative Sentiment: Commentary describes Lilly’s roughly $1.4 trillion valuation as reliant on high expectations; another analyst argues the shares are no longer a buy near record levels. This leaves the stock vulnerable if growth or pipeline progress disappoints. Article: Eli Lilly’s $1.4 trillion valuation is heavy with hope

Analyst Ratings Changes

LLY has been the subject of a number of recent research reports. Bank of America reissued a “buy” rating and issued a $1,497.00 price objective on shares of Eli Lilly and Company in a research note on Friday, October 30th. Cantor Fitzgerald lifted their price target on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an “overweight” rating in a report on Monday, November 2nd. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $1,330.00 to $1,500.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Guggenheim upped their price objective on Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. Finally, Truist Financial reaffirmed a “buy” rating and set a $1,612.00 price objective (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,422.00.

View Our Latest Research Report on Eli Lilly and Company

About Representative Rulli

Michael Rulli (Republican Party) is a member of the U.S. House, representing Ohio’s 6th Congressional District. He assumed office on June 25, 2024. His current term ends on January 3, 2027.

Rulli (Republican Party) is running for re-election to the U.S. House to represent Ohio’s 6th Congressional District. He declared candidacy for the 2026 election.

Michael Rulli graduated from Poland Seminary High School. He earned a degree from Emerson College. Rulli’s career experience includes working as the director of operations with Rulli Bros. Markets.

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Read More

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.